New pill could bring relief to eczema sufferers
NCT ID NCT07180511
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial is testing an experimental oral drug called QY201 in 460 adults with moderate to severe atopic dermatitis (eczema). Participants will take either QY201 or a placebo daily for 16 weeks. The main goals are to see if the drug can significantly clear the skin and reduce the severity of the condition. The study is currently enrolling by invitation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QY201 tablet
- What this could lead to
- If successful, this could provide a new oral treatment option for people with moderate to severe atopic dermatitis, helping to clear skin and reduce itching.
- What could go wrong
- This is still an experimental drug in Phase 3 testing. It may not work better than placebo, and side effects are possible. Results are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
EnitiateBioPharma
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin
- Menthol gloves may offer quick itch relief for eczema sufferers
- One pill may tame both itchy skin and stubborn liver disease